Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the Stifel Nicolaus 2012 Healthcare Conference on Thursday, September 6, 2012 at 8:35 am Eastern Time.
A live webcast of the presentation will be available via the “Investor Relations” page of the Antares website, www.antarespharma.com. A replay of the webcast will also be archived on Antares’ website for 90 days following the presentation.
About Antares Pharma
Antares Pharma focuses on self-injection pharmaceutical products and
topical gel-based medicines. The Company's subcutaneous and
intramuscular injection technology platforms include Vibex™ disposable
pressure-assisted auto injectors, disposable multi-use pen injectors and
Vision™ reusable needle-free injectors marketed as Tjet
® by Teva Pharmaceutical Industries, Ltd (Teva) and
Ferring Pharmaceuticals (Ferring), respectively. In the injector area,
Antares Pharma has a multi-product deal with Teva that includes
® human growth hormone (hGH) and a partnership with
Ferring that includes Zomacton
® hGH. In the gel-based area,
the Company's FDA approved product is Gelnique 3%™ for the treatment of
OAB (overactive bladder) marketed by Watson Pharmaceuticals, Inc. in the
U.S. Antares’ portfolio includes Elestrin
® (estradiol gel)
indicated for the treatment of moderate-to-severe vasomotor symptoms
associated with menopause, and marketed in the U.S. by Jazz
Pharmaceuticals. Antares Pharma has two facilities in the U.S. The
Parenteral Products Group located in Minneapolis, Minnesota directs the
manufacturing and marketing of the Company’s reusable needle-free
injection devices and related disposables, and develops its disposable
pressure-assisted auto injector and pen injector systems. The Company’s
corporate offices and Pharma Group are located in Ewing, New Jersey,
where pharmaceutical products are developed utilizing both the Company’s
transdermal systems and drug/device combination products.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV